The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans

Nat Commun. 2024 May 7;15(1):3844. doi: 10.1038/s41467-024-48091-w.

Abstract

Multiple myeloma (MM) is a heterogeneous disease characterized by frequent MYC translocations. Sporadic MYC activation in the germinal center of genetically engineered Vk*MYC mice is sufficient to induce plasma cell tumors in which a variety of secondary mutations are spontaneously acquired and selected over time. Analysis of 119 Vk*MYC myeloma reveals recurrent copy number alterations, structural variations, chromothripsis, driver mutations, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide (APOBEC) mutational activity, and a progressive decrease in immunoglobulin transcription that inversely correlates with proliferation. Moreover, we identify frequent insertional mutagenesis by endogenous retro-elements as a murine specific mechanism to activate NF-kB and IL6 signaling pathways shared with human MM. Despite the increased genomic complexity associated with progression, advanced tumors remain dependent on MYC. In summary, here we credential the Vk*MYC mouse as a unique resource to explore MM genomic evolution and describe a fully annotated collection of diverse and immortalized murine MM tumors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cell Transformation, Neoplastic / genetics
  • DNA Copy Number Variations / genetics
  • Genomics / methods
  • Humans
  • Mice
  • Mice, Transgenic
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / pathology
  • Mutagenesis, Insertional
  • Mutation
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Proto-Oncogene Proteins c-myc* / genetics
  • Proto-Oncogene Proteins c-myc* / metabolism
  • Signal Transduction / genetics
  • Translocation, Genetic

Substances

  • Proto-Oncogene Proteins c-myc
  • NF-kappa B